Integrated Analysis Identifies Novel Fusion Transcripts in Laterally Spreading Tumors Suggestive of Distinct Etiology Than Colorectal Cancers

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2022 Dec 8

PMID 36480069

Authors

Sandhya Rai

Manish Pratap Singh

Sameer Srivastava

Affiliations

Soon will be listed here.

Abstract

Background: Laterally spreading tumors (LSTs) of the colon and rectum are a class of abnormality which spreads laterally and appears ulcerated. They are a subclass of colorectal cancer (CRCs) with higher invasive potential than CRCs. Moreover, the etiology of LST still remains obscure.

Methods: This study aimed to identify unique fusion transcript(s) in LSTs and evaluate their role in LST development and progression. RNA-Seq data for LST samples from the EMBL-EBI database were used to identify fusion transcripts. An integrated approach using Gene Ontology, pathway analysis, hub gene, and co-expression network analysis functionally characterized fusion transcripts to shed light upon the etiology of LSTs.

Result: We identified 48 unique fusion genes in LSTs. GO terms were enriched in mRNA metabolic (p ≤ 2.06E-06), mRNA stabilization (p ≤ 1.60E-05), in cytosol (1.20E-05), RBP (p ≤ 2.30E-04), and RNA binding activity (p ≤ 3.51E-08) processes. Pathway analysis revealed an inflammatory phenotype of LSTs suggesting a distinct etiology than CRCs as pathways were enriched in salmonella infection (p ≤ 4.41 e-03), proteoglycans in cancer (p ≤ 1.18 e-02), and insulin signaling (p ≤ 2.13 e-02). Our exclusion and inclusion criteria and hub gene analysis finally identified 9 hub genes. Co-expression analysis of hub genes identified the most significant transcription factors (NELFE, MYC, TAF1, MAX) and kinases (MAPK14, CSNK2A1, CDK1, MAPK1) which were implicated in various cancer pathways. Furthermore, an overall survival analysis of hub genes was performed. Our predefined criterion resulted in the enrichment of NPM1-PTMA (NPM1: p ≤ 0.005) and HIST1H2BO-YBX1 (YBX1: p ≤ 0.02) fusion transcripts, significantly associated with the patient's overall survival.

Conclusion: Our systematic analysis resulted in novel fusion genes in LSTs suggesting a different etiology than CRCs. Fusion transcripts were observed more frequently in non-granular LSTs suggestive of genetically more unstable than granular LST. We hypothesize that NPM1-PTMA and HIST1H2BO-YBX1 could be implicated in LST development and progression and may also serve as a prognostic or diagnostic biomarker in future for better management of LSTs.

Citing Articles

Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors.

Liu R, Zhou J, Chen X, Zhang J, Chen Q, Liu X Biomedicines. 2025; 13(1).

PMID: 39857631 PMC: 11762367. DOI: 10.3390/biomedicines13010047.

Endoscopic submucosal dissection for superficial ultra-low rectal tumors: outcomes and predictive factors for procedure difficulty.

Wu Y, Xu Y, Lin H, Lin X, Deng W, Liang W Am J Cancer Res. 2025; 14(12):5784-5797.

PMID: 39803665 PMC: 11711545. DOI: 10.62347/PVVD6843.

Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies.

Salokas K, Dashi G, Varjosalo M Cancers (Basel). 2023; 15(14).

PMID: 37509339 PMC: 10377698. DOI: 10.3390/cancers15143678.

References

Facciorusso A, Antonino M, Di Maso M, Barone M, Muscatiello N . Non-polypoid colorectal neoplasms: Classification, therapy and follow-up. World J Gastroenterol. 2015; 21(17):5149-57. PMC: 4419055. DOI: 10.3748/wjg.v21.i17.5149. View

Xu M, Wang X, Li Q, Zhou P, Zhang Y, Zhong Y . Colorectal lateral spreading tumor subtypes: clinicopathology and outcome of endoscopic submucosal dissection. Int J Colorectal Dis. 2012; 28(1):63-72. DOI: 10.1007/s00384-012-1543-2. View

Hesson L, Ng B, Zarzour P, Srivastava S, Kwok C, Packham D . Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. Mol Cancer Res. 2016; 14(12):1217-1228. DOI: 10.1158/1541-7786.MCR-16-0175. View

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View

Dallol A, Morton D, Maher E, Latif F . SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 2003; 63(5):1054-8. View

Hiraoka S, Kato J, Tatsukawa M, Harada K, Fujita H, Morikawa T . Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology. 2006; 131(2):379-89. DOI: 10.1053/j.gastro.2006.04.027. View

Lee S, Li G, Kim S, Hong M, Jang J, Yoon N . NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget. 2015; 6(36):39028-35. PMC: 4770754. DOI: 10.18632/oncotarget.5494. View

Seshagiri S, Stawiski E, Durinck S, Modrusan Z, Storm E, Conboy C . Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488(7413):660-4. PMC: 3690621. DOI: 10.1038/nature11282. View

Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R . Identification and characterization of a novel rearrangement in a colorectal cancer patient. Oncotarget. 2017; 8(33):55353-55360. PMC: 5589663. DOI: 10.18632/oncotarget.19512. View

10.

Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield K, Chen S, Pine S . Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in Mutant Melanoma. Clin Cancer Res. 2017; 23(18):5631-5638. DOI: 10.1158/1078-0432.CCR-16-0758. View

11.

Ojima E, Inoue Y, Miki C, Mori M, Kusunoki M . Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy. J Gastroenterol. 2007; 42(9):730-6. DOI: 10.1007/s00535-007-2089-x. View

12.

Yu A, Chern Y, Zhang P, Pasiliao C, Rahman M, Chang G . Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT. Cancer Biol Ther. 2021; 22(2):112-123. PMC: 7928027. DOI: 10.1080/15384047.2020.1839278. View

13.

Li Z, Zhu Q, Zhang H, Hu Y, Wang G, Zhu Y . MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018; 10:6757-6768. PMC: 6289210. DOI: 10.2147/CMAR.S169406. View

14.

Russo A, Maiolino S, Pagliara V, Ungaro F, Tatangelo F, Leone A . Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles. Oncotarget. 2016; 7(48):79670-79687. PMC: 5346744. DOI: 10.18632/oncotarget.13216. View

15.

Nagasu S, Sudo T, Kinugasa T, Yomoda T, Fujiyoshi K, Shigaki T . Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer. Oncol Rep. 2019; 41(5):2889-2896. DOI: 10.3892/or.2019.7038. View

16.

Long J, Yin Y, Guo H, Li S, Sun Y, Zeng C . The mechanisms and clinical significance of PDCD4 in colorectal cancer. Gene. 2018; 680:59-64. DOI: 10.1016/j.gene.2018.09.034. View

17.

Nome T, Thomassen G, Bruun J, Ahlquist T, Bakken A, Hoff A . Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing. Transl Oncol. 2013; 6(5):546-53. PMC: 3799197. DOI: 10.1593/tlo.13457. View

18.

Li Z, Tognon C, Godinho F, Yasaitis L, Hock H, Herschkowitz J . ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell. 2007; 12(6):542-58. PMC: 2175032. DOI: 10.1016/j.ccr.2007.11.012. View

19.

Tognon C, Knezevich S, Huntsman D, Roskelley C, Melnyk N, Mathers J . Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002; 2(5):367-76. DOI: 10.1016/s1535-6108(02)00180-0. View

20.

Parker B, Engels M, Annala M, Zhang W . Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 2014; 232(1):4-15. DOI: 10.1002/path.4297. View